Home›Companies›Healthcare›Sailie Bio

Sailie Bio, Inc.

Develops sensors for researchers to measure biomarkers, including hormones in saliva.

Updated Nov 10, 2026·Latest SEC filing Jul 14, 2026·Suggest an edit

About Sailie Bio

Sailie Bio is a private company based in Boston, Massachusetts, incorporated in 2025 in Delaware. It has reported $100,000 raised in one offering on Form D since July 2026. Its chief executive is Gregory Dracoulis.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Jun 28, 2026Jul 14, 2026$100,000of $250K target2$50,000Simple Agreement for Future Equity (SAFE)Rule 506(b)Form D ↗

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Sailie Bio's Form D filed Jul 14, 2026.

GD
Gregory Dracoulis
President and Chief Executive Officer, director

Sources

  1. SECSailie Bio, Inc. filing history